Leena Gandhi
Dana-Farber Cancer Institute
3 papers in the Anchorcite directory, published between 2010 and 2018, cited 17,528 times in total.
ORCID profileResearch topics
- Lung Cancer Treatments and Mutations · 3 papers
- Cancer Immunotherapy and Biomarkers · 2 papers
- Lung Cancer Diagnosis and Treatment · 2 papers
- Lung Cancer Research Studies · 2 papers
Frequent co-authors
- Enriqueta Felip · 2 papers
- Rina Hui · 2 papers
- Edward B. Garon · 2 papers
- Delvys Rodríguez‐Abreu · 1 paper
- Shirish M. Gadgeel · 1 paper
- Emilio Esteban · 1 paper
- Flávia De Angelis · 1 paper
- Manuel Dómine · 1 paper
Papers
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine · 2010 · 4,480 citations
BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in…
Metadata from OpenAlex (CC0).